Newsroom

university of washington’s baker lab and google deepmind redefine protein science, paving the way for ai-driven biotherapeutics victoria, british columbia (canada), october 10, 2024 – immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today celebrates the recent nobel prize in chemistry awarded to david baker of the university of washington, seattle, wa, usa, "for computational protein design," and jointly to demis hassabis and john m. jumper of google deepmind, london, uk, "for protein structure prediction." this accolade highlights the vital role of computational tools and ai in advancing our understanding of protein structures—principles that are central to ipa’s research initiatives. these achievements validate the methodologies that underpin ipa’s proprietary foundation ai model, lensai, which leverages similar computational and ai approaches to innovate drug discovery. "as ipa continues to enhance lensai, our proprietary ai platform, we remain committed to leveraging cutting-edge technologies to unravel complex protein interactions. the nobel prize recognition of alphafold underscores the growing importance of ai in scientific breakthroughs. at immunoprecise antibodies, we're dedicated to integrating advanced ai technologies into our workflows, which not only amplifies our capabilities in drug development but also aligns with our mission to pioneer innovative biotherapeutic solutions," said dr. jennifer bath, ceo of immunoprecise antibodies. at ipa, the integration of alphafold, an open-access ai tool developed by google deepmind, into our drug discovery processes has revolutionized how we approach complex biological challenges. by leveraging alphafold's freely available protein structure predictions, ipa enhances the design and optimization of antibodies, making significant strides in developing treatments for diseases that were previously deemed intractable. “our hyft technology amplifies the power of alphafold and other foundational ai models by providing deeper biological context. hyft identifies key functional and structural motifs within protein sequences, enhancing the precision of alphafold's predictions and extending its application in drug discovery, said dr. van hyfte, head of innovation at biostrand. “this combination enables us to push the boundaries of what’s possible in biotherapeutic development, accelerating the path from prediction to solution.” for a deeper dive into alphafold's impact on drug discovery and its integration into ipa's technology stack, explore their subsidiary, biostrand's, blog post: explained: a brief look into alphafold 2. looking ahead, ipa is keen to expand partnerships within academia and industry to further explore ai's potential in developing novel therapies. ipa invites interested parties to join in advancing the application of lensai, aiming for a future where diseases are not merely treated but understood and prevented. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com forward-looking statement this press release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “expects” “estimates”, “intends”, “anticipates” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “would”, “might” or “will” be taken, occur or be achieved. forward–looking statements include, but are not limited to, statements regarding computational and ai approaches to innovate drug discovery. . although the company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. our actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the united states, canada or internationally. you should also consult our quarterly and annual filings with the canadian and u.s. securities commissions for additional information on risks and uncertainties. these forward–looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual report on form 20-f for the year ended april 30, 2024 (which may be viewed on the company’s sedar+ profile at www.sedar.ca and edgar profile at www.sec.gov/edgar). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source: immunoprecise antibodies ltd.

victoria, british columbia, june 6, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”) today introduced a transformative ai-driven rapid therapeutic screening platform, the result of a collaboration between ipa canada and its subsidiary, biostrand®. this innovative solution aims to significantly expedite the early stages of drug discovery by enabling the early elimination of less promising therapeutic candidates, thereby reducing time, cost, and the risk of failure during later stage discovery. the current transgenic animal model market, reaching usd 17.7 billion in 2021 and expected to grow by 8.1% cagr from 2022 to 2028¹, has been widely adopted in novel therapeutic discovery, primarily to avoid what was previously seen as time-consuming, expensive, risk-laden, and sometimes unsuccessful humanization processes. however, despite its widespread adoption, transgenics pose limitations of their own, such as a lack of diversity in therapeutic outputs, loss of therapeutic efficacy, and high costs. addressing these challenges, biostrand's recently patented technology introduces a reliable, scalable, and cost-effective alternative for early-stage therapeutic discovery. biostrand’s platform, termed the hyft® proprietary proteome presence assessment, optimizes potential therapeutic drug candidates at an early stage using the multi-functional lensai™ in silico humanization platform integrated with its patented hyft technology. this allows a multitude of potential therapies to be analyzed concurrently, reducing analysis time and costs, and ensuring that only the most promising candidates proceed further into the drug discovery process. (left) traditional antibody discovery and development timeline. linear model imposes increased risk of attrition due to the cost of lead candidate advancement with minimal insight into future clinical viability. (right) the new enhanced predictive insights gained by ipa’s new in silico-driven discovery cycle, which increases the probability of clinical success, saving our partners time and money. the concept of in silico humanization refers to the computational process of making an antibody or protein from a non-human source resemble human proteins. this is crucial for reducing the likelihood of immune responses against therapeutics, while preserving their functionality. biostrand's patented hyft technology, incorporated into their proprietary lensai software, screens the entire human proteome (the entire complement of proteins that is or can be expressed by a cell, tissue, or organism), as well as various animal proteomes, against candidate therapeutics. this screening is accomplished in under one minute per candidate molecule. this process advances the most 'human-like' molecules, speeding up humanization, reducing the manipulation required before use in clinical trials, and offering a rapid, scalable, and cost-effective alternative to transgenic animal models. other existing methods can only assess candidates against a subset of the human proteome, which can result in an incomplete evaluation of a protein's humanness and immunogenicity. hyft technology, however, uniquely addresses this limitation with several distinct advantages, including: use of the most comprehensive human proteome reference set, enabling more thorough comparisons. the ability to extract unique universal fingerprint™ patterns from biological sequences. the capacity to compare the humanized therapeutics to the human proteome, evaluating its similarity to endogenous proteins. the ability to capture both sequence and structural information, enabling a better understanding of the protein's function. scalability and high-throughput capabilities, allowing for rapid assessments of numerous candidate proteins against extensive reference datasets. leveraging these unique capabilities, the hyft proprietary proteome presence assessment offers a more accurate and complete assessment of candidates' humanness and immunogenicity. this supports the development of safer, more effective therapeutic proteins and antibodies while greatly streamlining the drug development process. "ipa's smooth fusion of computer-driven humanization and immunogenicity testing paves the way for faster development and boosts the potential of new treatment methods," stated dr. ingrid brands, co-founder and general manager of biostrand. "our dedication to innovation and pushing the limits of ai-driven therapeutic discovery is represented in this collaboration and integration. we're all about setting new standards in medicine and driving value for our investors.” ipa has provided insights into its strategic approach for monetizing this breakthrough technology. the plan involves targeting their extensive existing client base, which includes 19 of the top 20 pharmaceutical companies and hundreds of biotechnology firms. these clients typically face substantial costs, when using transgenic animals, to progress a single therapeutic candidate through the commercialization process. these costs often reach tens to hundreds of millions of dollars per molecule, encompassing upfront payments, milestone payments, and commercial royalties. by introducing a more reliable, efficient, and cost-effective solution via ipa's ai-driven platform, the company is well-positioned to provide greater results and value for its clients, reducing their costs and accelerating their drug discovery timelines. this increase in quality, productivity, and value is expected to translate directly into increased revenue streams for ipa, fostering substantial financial growth for the company and its investors. ¹ https://www.gminsights.com/industry-analysis/animal-model-market about biostrand’s hyft technology biostrand's hyft technology extracts unique patterns, known as universal fingerprint™ patterns, from the entire biosphere, and integrates them with various data sources, such as scientific papers and medical records. the resulting knowledge graph encompasses over 660 million hyfts and more than 25 billion relations, providing a powerful resource for researchers and ai-driven analysis. the lensai platform, powered by hyft technology, takes advantage of the latest advancements in large language models (llms) to bridge the gap between syntax (sequences) and semantics (functions). this enables the platform to extract valuable insights from vast amounts of data, without the limitations of traditional llms. ipa's support of biostrand's pioneering work reinforces its commitment to investing in cutting-edge biotechnology solutions with the potential to transform the industry. about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the drug development process of the integration of ipa’s lensai in silico humanization platform with its hyft technology, and statements relating to ipa’s expected increased revenue streams and financial growth . in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai in silico humanization platform with its hyft technology may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

company to present at the upcoming 2023 annual meeting of the american association for cancer research (aacr) immunoprecise’s unique proprietary bispecific antibodies link cells expressing tumor-associated antigen tropomyosin receptor kinase b (trkb) with cd3-positive t cells, immune system cells that respond by recognizing and eliminating cancer cells. the company’s potential therapeutic, which is designed to bring trkb-expressing tumor cells in contact with engaged and activated t cells, may represent a novel first-in-class therapeutic for targeting trkb-associated tumors in such cancers as non-small cell lung, breast, colon, head, neck, and pancreatic. studies show most tumors from these cancers express high levels of trkb1, and the protein’s presence is associated with poor prognosis and low survival rates. the company has filed a provisional patent application to the united state patent and trademark office. victoria, british colombia march 23, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), an ai-driven biotherapeutic research and technology company, is pleased to announce that its wholly owned subsidiary, talem therapeutics, will present a scientific poster with their latest data on the development of bispecific t-cell engagers targeting trkb at the annual aacr meeting in orlando, florida, which is held from april 14 to 19, 2023. with this advanced development to target trkb-expressing tumor cells, ipa differentiates itself from other organizations developing immunotherapeutics to treat malignant solid tumors. the (over)expression of trkb and (over)activation of the trkb-signaling pathway play a crucial role in various malignancies and are associated with poor disease outcomes. currently applied pharmaceuticals target trkb through interference with its tyrosine kinase activity, but they lack specificity and are therefore associated with many adverse effects. at the 2023 annual aacr meeting, ipa will present their novel therapeutic design, exhibiting high specificity to the tumor-associated protein trkb, shown to be associated with cancer cell survival, proliferation, migration, and resistance to chemotherapy. the company will share data demonstrating the evidence for the potential therapeutic’s ability to recruit and activate t cells to target trkb-specific tumors, in what they believe may be a safer, more effective, and more targeted cancer therapy. the importance of the invention was appreciated in a provisional patent application filed by talem therapeutics to the united state patent and trademark office. dr. jennifer bath, ipa’s ceo and president, stated: “for years, we have consistently demonstrated success in creating clinically relevant therapies for our clients and partners by utilizing our advanced drug discovery and analytical capabilities. we take pride in revealing the details of a pioneering bispecific therapy that aims to revolutionize the approach to targeting and treating various solid tumors. our continuous goal is to create safer and more precise therapies, as we collaborate with our partners to develop the future generation of cancer treatment options.” the poster presentation “bispecific t cell engagers targeting trkb” ipa will exhibit their poster number 29 in section 25 on monday april 17th, from 9.00 am to 12.30 pm. the session category is ‘immunology’, and the session is entitled ‘therapeutic antibodies 1’. an abstract of the poster is presented under number 1890. 1. meng, l.; liu, b.; ji, r.; jiang, x.; yan, x.; xin, y. targeting the bdnf/trkb pathway for the treatment of tumors (review). oncol lett 2018. https://doi.org/10.3892/ol.2018.9854. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the safe activation of t cells, regarding therapeutic potential of ipa’s trkb x cd3 bispecific antibodies to treat trkb-related tumors, and the company’s ability to complete the development of their tatx-200 program. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models, wet-lab experiments and preclinical studies may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies